Liying Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liying Xu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Yurong Zhou
Department of Radiology, Zhongnan Hospital of Wuhan University , Wuhan, Hubei
3 shared publications- Yao Sun
College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, China
2 shared publications Yu Zhou
Department of Radiology, Zhongnan Hospital of Wuhan University , Wuhan, Hubei
2 shared publicationsZhou Zhou
Department of Radiology, Zhongnan Hospital of Wuhan University , Wuhan, Hubei
2 shared publicationsChang Liu
Key Laboratory of Pesticide and Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, P. R. China
1 shared publicationChangling Dong
Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, No. 169, Donghu Road, Wuchang District, Wuhan 430071, Hubei, China
1 shared publication
Latest Publications
- Open Access
- 23 July 2026
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 8 (5) , 495-508
Dual-Layer Spectral CT-Based Models for the Differential Diagnosis of Breast Lesions
Objective: To develop a hybrid model integrating morphological features with quantitative parameters from dual-layer spectral computed tomography (DSCT) to noninvasively differentiate benign breast lesions from breast cancer. Methods: This retrospective study included patients with breast lesions incidentally detected on spectral CT between January 2020 and May 2024. Lesions were categorized as benign or malignant based on histopathology or greater than two years’ stability on follow-up imaging. Clinical variables, morphological characteristics, and DSCT parameters were collected. The cohort was randomly divided into training, validation, and independent testing sets using stratified sampling. Feature selection was performed exclusively within the training set using univariate analysis, collinearity assessment, and least absolute shrinkage and selection operator regression with the one–standard-error criterion. Clinico-radiological, DSCT-based, and hybrid models were constructed using multivariate logistic regression. Model discrimination was evaluated using receiver operating characteristic analysis and, model stability was assessed using nested cross-validation. A nomogram was constructed based on the best-performing model. Results: A total of 102 patients (mean age 52 ± 11 years) were included, including 27 patients (26%) with benign breast lesions and 75 patients (74%) with breast cancer. In the independent testing set, the DSCT-based model outperformed the clinical-radiological model (AUC = 0.967 vs 0.933), while the hybrid model achieved the highest diagnostic performance (AUC, 0.983). Calibration curves demonstrated strong concordance between predicted and observed outcomes. Decision curve analysis indicated favorable net benefit. Conclusion: The hybrid model demonstrated good diagnostic performance in noninvasively differentiating benign from malignant breast lesions detected preoperatively on DSCT.
- 23 July 2026
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 8 (5) , 495-508
Open AccessDual-Layer Spectral CT-Based Models for the Differential Diagnosis of Breast Lesions
Objective: To develop a hybrid model integrating morphological features with quantitative parameters from dual-layer spectral computed tomography (DSCT) to noninvasively differentiate benign breast lesions from breast cancer. Methods: This retrospective study included patients with breast lesions incidentally detected on spectral CT between January 2020 and May 2024. Lesions were categorized as benign or malignant based on histopathology or greater than two years’ stability on follow-up imaging. Clinical variables, morphological characteristics, and DSCT parameters were collected. The cohort was randomly divided into training, validation, and independent testing sets using stratified sampling. Feature selection was performed exclusively within the training set using univariate analysis, collinearity assessment, and least absolute shrinkage and selection operator regression with the one–standard-error criterion. Clinico-radiological, DSCT-based, and hybrid models were constructed using multivariate logistic regression. Model discrimination was evaluated using receiver operating characteristic analysis and, model stability was assessed using nested cross-validation. A nomogram was constructed based on the best-performing model. Results: A total of 102 patients (mean age 52 ± 11 years) were included, including 27 patients (26%) with benign breast lesions and 75 patients (74%) with breast cancer. In the independent testing set, the DSCT-based model outperformed the clinical-radiological model (AUC = 0.967 vs 0.933), while the hybrid model achieved the highest diagnostic performance (AUC, 0.983). Calibration curves demonstrated strong concordance between predicted and observed outcomes. Decision curve analysis indicated favorable net benefit. Conclusion: The hybrid model demonstrated good diagnostic performance in noninvasively differentiating benign from malignant breast lesions detected preoperatively on DSCT.
- 7 May 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (42) , 10737-10740
Molecular engineering of asymmetric aza-BODIPY dyes for high-performance phototherapy
Achieving both anti-fluorescence and anti-ROS quenching effects remains a challenge for conventional small-molecule dyes.
- 7 May 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (42) , 10737-10740
Molecular engineering of asymmetric aza-BODIPY dyes for high-performance phototherapy
Achieving both anti-fluorescence and anti-ROS quenching effects remains a challenge for conventional small-molecule dyes.
- Open Access
- 22 April 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
Time-dependent diffusion MRI as in vivo histology: microstructural biomarkers for breast cancer diagnosis and prognostic stratification
Time-dependent diffusion MRI (TD-dMRI) holds potential for characterizing tumor cell properties; however, its utility in diagnosing various breast lesions
- 22 April 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
Open AccessTime-dependent diffusion MRI as in vivo histology: microstructural biomarkers for breast cancer diagnosis and prognostic stratification
Time-dependent diffusion MRI (TD-dMRI) holds potential for characterizing tumor cell properties; however, its utility in diagnosing various breast lesions
- Open Access
- 12 March 2026
- Published by Springer Nature in Chinese Journal of Academic Radiology
- Vol. 9 (2) , 87-96
Diagnostic value of DLCT multiparametric analysis in differentiating small pulmonary oligometastases from benign lung nodules
- 12 March 2026
- Published by Springer Nature in Chinese Journal of Academic Radiology
- Vol. 9 (2) , 87-96
Open AccessDiagnostic value of DLCT multiparametric analysis in differentiating small pulmonary oligometastases from benign lung nodules
- 19 August 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (10) , 5824-5830
Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent
The aim of this study was to synthesize a quinoline-based MRI contrast agent, Gd-DOTA-FAPI04, and assess its capacity for targeting fibroblast activation protein (FAP)-positive tumors in vivo. Gd-DOTA-FAPI04 was synthesized by attaching a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) complex of gadolinium(III) to FAP inhibitor FAPI04. The longitudinal relaxation time (T1) of the contrast agent was measured using a Siemens Prisma 3.0T MR system, and the CCK-8 assay was performed to evaluate its potential cytotoxicity. Male nude mice bearing tumors grown from FAP-expressing fibrosarcoma cells were divided into experimental (n = 4) and control (n = 4) groups, and T1-weighted image enhancement was measured at different times (0, 10, 30, 60, 90, and 120 min) postinjection of Gd-DOTA-FAPI04. The control group received an additional preinjection of excess FAPI04. FAP expression in tumor tissue was investigated by using immunohistochemistry with an anti-FAP antibody. The longitudinal relaxivities of gadodiamide and Gd-DOTA-FAPI04 were measured to be 3.734 mM-1 s-1 and 5.323 mM-1 s-1, respectively. The CCK-8 assay demonstrated that Gd-DOTA-FAPI04 has minimal toxicity to cultured human fibrosarcoma cells. In vivo MRI showed that peak accumulation of Gd-DOTA-FAPI04 in FAP-expressing tumors occurred 1 h postinjection and could be blocked by preinjection of excess FAPI04. Immunohistochemical analysis of harvested tumor tissue supported the above findings. Gd-DOTA-FAPI04 is a promising contrast agent for in vivo imaging of FAP.
- 19 August 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (10) , 5824-5830
Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent
The aim of this study was to synthesize a quinoline-based MRI contrast agent, Gd-DOTA-FAPI04, and assess its capacity for targeting fibroblast activation protein (FAP)-positive tumors in vivo. Gd-DOTA-FAPI04 was synthesized by attaching a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) complex of gadolinium(III) to FAP inhibitor FAPI04. The longitudinal relaxation time (T1) of the contrast agent was measured using a Siemens Prisma 3.0T MR system, and the CCK-8 assay was performed to evaluate its potential cytotoxicity. Male nude mice bearing tumors grown from FAP-expressing fibrosarcoma cells were divided into experimental (n = 4) and control (n = 4) groups, and T1-weighted image enhancement was measured at different times (0, 10, 30, 60, 90, and 120 min) postinjection of Gd-DOTA-FAPI04. The control group received an additional preinjection of excess FAPI04. FAP expression in tumor tissue was investigated by using immunohistochemistry with an anti-FAP antibody. The longitudinal relaxivities of gadodiamide and Gd-DOTA-FAPI04 were measured to be 3.734 mM-1 s-1 and 5.323 mM-1 s-1, respectively. The CCK-8 assay demonstrated that Gd-DOTA-FAPI04 has minimal toxicity to cultured human fibrosarcoma cells. In vivo MRI showed that peak accumulation of Gd-DOTA-FAPI04 in FAP-expressing tumors occurred 1 h postinjection and could be blocked by preinjection of excess FAPI04. Immunohistochemical analysis of harvested tumor tissue supported the above findings. Gd-DOTA-FAPI04 is a promising contrast agent for in vivo imaging of FAP.
- 1 June 2023
- Published by American Scientific Publishers in Journal of Biobased Materials and Bioenergy
- Vol. 17 (3) , 345-349
Therapeutic and Clinical Nursing Values of Momordica charantia Extracts Combined with Hedyotis diffusa on Lung Cancer
The separation and identification of bioactive substances that come from natural resources have aroused increasing attention. Momordica charantia (M. charantia) has a variety of bio-activities, containing anti-oxidation, immune regulation, anti-tumor, radiation protection, anti-diabetes, and liver protection. After the extraction new substances from Momordica charantia, their treatment effect on lung cancer combined with Hedyotis diffusa was determined and the related mechanism was explored as well in this study. Firstly, the CCK-8 assay was conducted and the inhibition of the new substances combined with Hedyotis diffusa. Next, the real time RT-PCR was conducted and the relative expression of the VEGF in the cancer cells was determined. In addition, the complete chloroplast genome sequence of M. charantia is followed by the phylogenetic analysis.
- 1 June 2023
- Published by American Scientific Publishers in Journal of Biobased Materials and Bioenergy
- Vol. 17 (3) , 345-349
Therapeutic and Clinical Nursing Values of Momordica charantia Extracts Combined with Hedyotis diffusa on Lung Cancer
The separation and identification of bioactive substances that come from natural resources have aroused increasing attention. Momordica charantia (M. charantia) has a variety of bio-activities, containing anti-oxidation, immune regulation, anti-tumor, radiation protection, anti-diabetes, and liver protection. After the extraction new substances from Momordica charantia, their treatment effect on lung cancer combined with Hedyotis diffusa was determined and the related mechanism was explored as well in this study. Firstly, the CCK-8 assay was conducted and the inhibition of the new substances combined with Hedyotis diffusa. Next, the real time RT-PCR was conducted and the relative expression of the VEGF in the cancer cells was determined. In addition, the complete chloroplast genome sequence of M. charantia is followed by the phylogenetic analysis.
- Open Access
- 10 October 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 967655
Detection of axillary lymph node metastasis in breast cancer using dual-layer spectral computed tomography
Purpose: To investigate the value of contrast-enhanced dual-layer spectral computed tomography (DLCT) in the detection of axillary lymph node (ALN) metastasis in breast cancer.Materials and Methods: In this prospective study, 31 females with breast cancer underwent contrast-enhanced DLCT from August 2019 to June 2020. All ALNs were confirmed by postoperative histology. Spectral quantitative parameters, including λHU (in Hounsfield units per kiloelectron-volt), nIC (normalized iodine concentration), and Zeff (Z-effective value) in both arterial and delay phases, were calculated and contrasted between metastatic and nonmetastatic ALNs using the McNemar test. Discriminating performance from metastatic and nonmetastatic ALNs was analyzed using receiver operating characteristic curves.Results: In total, 132 ALNs (52 metastatic and 80 nonmetastatic) were successfully matched between surgical labels and preoperative labels on DLCT images. All spectral quantitative parameters (λHu, nIC, and Zeff) derived from both arterial and delayed phases were greater in metastatic ALNs than in nonmetastatic SLNs (all p < 0.001). Logistic regression analyses showed that λHu in the delayed phase was the best single parameter for the detection of metastatic ALNs on a per-lymph node basis, with an area under the curve of 0.93, accuracy of 86.4% (114/132), sensitivity of 92.3% (48/52), and specificity of 87.5% (70/80).Conclusion: The spectral quantitative parameters derived from contrast-enhanced DLCT, such as λHu, can be applied for the preoperative detection of ALN metastasis in breast cancer.
- 10 October 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 967655
Open AccessDetection of axillary lymph node metastasis in breast cancer using dual-layer spectral computed tomography
Purpose: To investigate the value of contrast-enhanced dual-layer spectral computed tomography (DLCT) in the detection of axillary lymph node (ALN) metastasis in breast cancer.Materials and Methods: In this prospective study, 31 females with breast cancer underwent contrast-enhanced DLCT from August 2019 to June 2020. All ALNs were confirmed by postoperative histology. Spectral quantitative parameters, including λHU (in Hounsfield units per kiloelectron-volt), nIC (normalized iodine concentration), and Zeff (Z-effective value) in both arterial and delay phases, were calculated and contrasted between metastatic and nonmetastatic ALNs using the McNemar test. Discriminating performance from metastatic and nonmetastatic ALNs was analyzed using receiver operating characteristic curves.Results: In total, 132 ALNs (52 metastatic and 80 nonmetastatic) were successfully matched between surgical labels and preoperative labels on DLCT images. All spectral quantitative parameters (λHu, nIC, and Zeff) derived from both arterial and delayed phases were greater in metastatic ALNs than in nonmetastatic SLNs (all p < 0.001). Logistic regression analyses showed that λHu in the delayed phase was the best single parameter for the detection of metastatic ALNs on a per-lymph node basis, with an area under the curve of 0.93, accuracy of 86.4% (114/132), sensitivity of 92.3% (48/52), and specificity of 87.5% (70/80).Conclusion: The spectral quantitative parameters derived from contrast-enhanced DLCT, such as λHu, can be applied for the preoperative detection of ALN metastasis in breast cancer.
- 20 July 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (65) , 9068-9071
Rationally designed Ru( ii ) metallacycles with tunable imidazole ligands for synergistical chemo-phototherapy of cancer
Herein, we construct a series of Ru( ii ) metallacycles with multimodal chemo-phototherapeutic properties, which exhibited much higher anticancer activity and better cancer-cell selectivity than cisplatin.
- 20 July 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (65) , 9068-9071
Rationally designed Ru( ii ) metallacycles with tunable imidazole ligands for synergistical chemo-phototherapy of cancer
Herein, we construct a series of Ru( ii ) metallacycles with multimodal chemo-phototherapeutic properties, which exhibited much higher anticancer activity and better cancer-cell selectivity than cisplatin.
- Open Access
- 4 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Case Report: Intercostal Lymph Node Metastasis: A Case Report and Review of the Literature
The axillary lymph nodes are the primary group responsible for lymphatic drainage in the breast and, consequently, are the most common location for breast cancer metastasis. However, lymphatic pathways running from the breast, via intercostal spaces, to parasternal lymph vessels have also been identified. According to the American Joint Committee on Cancer eighth edition manual, regional lymph node metastasis normally travels to the ipsilateral axillary, supraclavicular, subclavicular, and internal mammary lymph nodes. The presence of intercostal metastasis is out the range of these regional lymph nodes. It is very rare for intercostal lymph nodes to be the extra-axillary site of metastasis in breast cancer, and it has been little reported on in the literature. Despite its rarity, it has the capacity to adversely affect the prognosis of breast cancer and drastically influence treatment choice. Here, we analyze such a case, with a patient receiving a radical mastectomy and metastatic intercostal lymph node dissection due to the presence of intercostal lymph node metastasis indicated via MRI. Furthermore, the potential application of preoperative 3-dimensional (3D) visualization and surgical planning is also discussed.
- 4 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessCase Report: Intercostal Lymph Node Metastasis: A Case Report and Review of the Literature
The axillary lymph nodes are the primary group responsible for lymphatic drainage in the breast and, consequently, are the most common location for breast cancer metastasis. However, lymphatic pathways running from the breast, via intercostal spaces, to parasternal lymph vessels have also been identified. According to the American Joint Committee on Cancer eighth edition manual, regional lymph node metastasis normally travels to the ipsilateral axillary, supraclavicular, subclavicular, and internal mammary lymph nodes. The presence of intercostal metastasis is out the range of these regional lymph nodes. It is very rare for intercostal lymph nodes to be the extra-axillary site of metastasis in breast cancer, and it has been little reported on in the literature. Despite its rarity, it has the capacity to adversely affect the prognosis of breast cancer and drastically influence treatment choice. Here, we analyze such a case, with a patient receiving a radical mastectomy and metastatic intercostal lymph node dissection due to the presence of intercostal lymph node metastasis indicated via MRI. Furthermore, the potential application of preoperative 3-dimensional (3D) visualization and surgical planning is also discussed.